A systematic study of Erzhu Erchen decoction against damp-heat internalized type 2 diabetes based on data mining and experimental verification

Background:Erzhu Erchen decoction(EZECD),which is based on Erchen decoction and enhanced with Atractylodes lancea and Atractylodes macrocephala,is widely used for the treatment of dampness and heat(The clinical manifestations of Western medicine include thirst,inability to drink more,diarrhea,yellow urine,red tongue,et al.)internalized disease.Nevertheless,the mechanism of EZECD on damp-heat internalized Type 2 diabetes(T2D)remains unknown.We employed data mining,pharmacology databases and experimental verification to study how EZECD treats damp-heat internalized T2D.Methods:The main compounds or genes of EZECD and damp-heat internalized T2D were obtained from the pharmacology databases.Succeeding,the overlapped targets of EZECD and damp-heat internalized T2D were performed by the Gene Ontology,kyoto encyclopedia of genes and genomes analysis.And the compound-disease targets-pathway network were constructed to obtain the hub compound.Moreover,the hub genes and core related pathways were mined with weighted gene co-expression network analysis based on Gene Expression Omnibus database,the capability of hub compound and genes was valid in AutoDock 1.5.7.Furthermore,and violin plot and gene set enrichment analysis were performed to explore the role of hub genes in damp-heat internalized T2D.Finally,the interactions of hub compound and genes were explored using Comparative Toxicogenomics Database and quantitative polymerase chain reaction.Results:First,herb-compounds-genes-disease network illustrated that the hub compound of EZECD for damp-heat internalized T2D could be quercetin.Consistently,the hub genes were CASP8,CCL2,and AHR according to weighted gene co-expression network analysis.Molecular docking showed that quercetin could bind with the hub genes.Further,gene set enrichment analysis and Gene Ontology represented that CASP8,or CCL2,is negatively involved in insulin secretion response to the TNF or lipopolysaccharide process,and AHR or CCL2 positively regulated lipid and atherosclerosis,and/or including NOD-like receptor signaling pathway,and TNF signaling pathway.Ultimately,the quantitative polymerase chain reaction and western blotting analysis showed that quercetin could down-regulated the mRNA and protein experssion of CASP8,CCL2,and AHR.It was consistent with the results in Comparative Toxicogenomics Database databases.Conclusion:These results demonstrated quercetin could inhibit the expression of CASP8,CCL2,AHR in damp-heat internalized T2D,which improves insulin secretion and inhibits lipid and atherosclerosis,as well as/or including NOD-like receptor signaling pathway,and TNF signaling pathway,suggesting that EZECD may be more effective to treat damp-heat internalized T2D.

Clinicopathological features and expression of regulatory mechanism of the Wnt signaling pathway in colorectal sessile serrated adenomas/polyps with different syndrome types

BACKGROUND Colorectal cancer(CRC)is the third most common cancer worldwide,with the fourth highest mortality among all cancers.Reportedly,in addition to adenomas,serrated polyps,which account for 15%-30%of CRCs,can also develop into CRCs through the serrated pathway.Sessile serrated adenomas/polyps(SSAs/Ps),a type of serrated polyps,are easily misdiagnosed during endoscopy.AIM To observe the difference in the Wnt signaling pathway expression in SSAs/Ps patients with different syndrome types.METHODS From January 2021 to December 2021,patients with SSAs/Ps were recruited from the Endoscopy Room of Shanghai Traditional Chinese Medicine-Integrated Hospital,affiliated with Shanghai University of Traditional Chinese Medicine.Thirty cases each of large intestine damp-heat(Da-Chang-Shi-Re,DCSR)syndrome and spleen-stomach weakness(Pi-Wei-Xu-Ruo)syndrome were reported.Baseline comparison of the general data,typical tongue coating,colonoscopy findings,and hematoxylin and eosin findings was performed in each group.The expression of the Wnt pathway-related proteins,namelyβ-catenin,adenomatous polyposis coli,and mutated in colorectal cancer,were analyzed using immunohistochemistry.RESULTS Significant differences were observed with respect to the SSAs/Ps size between the two groups of patients with different syndrome types(P=0.001).The other aspects did not differ between the two groups.The Wnt signaling pathway was activated in patients with SSAs/Ps belonging to both groups,which was manifested asβ-catenin protein translocation into the nucleus.However,SSAs/Ps patients with DCSR syndrome had more nucleation,higherβ-catenin expression,and negative regulatory factor(adenomatous polyposis coli and mutated in colorectal cancer)expression(P<0.0001)than SSA/P patients with Pi-Wei-Xu-Ruo syndrome.In addition,the SSA/P size was linearly correlated with the related protein expression.CONCLUSION Patients with DCSR syndrome had a more obvious Wnt signaling pathway activation and a higher risk of carcinogenesis.A high-quality colonoscopic diagnosis was essential.The thorough assessment of clinical diseases can be improved by combining the diseases of Western medicine with the syndromes of traditional Chinese medicine.

Efficacy of Pidan Jianqing decoction in treatment of type 2 diabetes with spleen deficiency and damp-heat syndrome

Introduction:This study aimed to assess the clinical efficacy of Pidan Jianqing decoction in the treatment of type 2 diabetes.Methods:A total of 72 patients with type 2 diabetes differentiated as spleen deficiency with damp-heat syndrome were randomly assigned to a treatment group(n=35)or control group(n=32).Patients in the control group received diet and exercise guidance and medication in the form of 0.5 g metformin hydrochloride tablets,while patients in the treatment group received Pidan Jianqing decoction in addition to the treatment given to the control group.Efficacy was evaluated after 8 weeks of treatment.Results:Efficacy was 91.4%in the treatment group versus 68.8%in the control group,which was a statistically significant difference(P<0.05).Significant group differences were also noted in the number of patients with improvement in symptoms such as dry mouth and polydipsia,frequency of urination and polyuria,abdominal distention and loss of appetite,fatigue and weakness,and sticky stools(all P<0.05),with greater improvement in the treatment group compared to the control group.The fasting blood glucose(FBG)and 2 h postprandial blood glucose levels significantly improved in both groups after treatment(P<0.05);however,there was no significant difference in glycated hemoglobin levels before and after treatment in both groups.Conclusion:Pidan Jianqing decoction can lower blood glucose levels and improve symptoms in patients with type 2 diabetes.

Clinical Efficacy of Western Medicine Combined with Chinese Medicine for Pelvic Inflammatory Disease(Damp-Heat and Stasis Type)

Objective:This study was undertaken to evaluate the clinical efficacy of Western medicine combined with Chinese medicine for pelvic inflammatory disease(damp-heat and stasis type).Methods:Seventy-four patients who were diagnosed with pelvic inflammatory disease(damp-heat and stasis type)by our hospital during July 2021 to July 2022 were randomized into two groups:the participants in the control group received conventional Western medicine treatment,and the participants in the study group received Western medicine combined with Chinese medicine.Results:After treatment,the total effectiveness of the control group(72.98%)was significantly lower than that of the study group(94.59%),(P<0.05);the whole blood viscosity high cut,whole blood viscosity low cut,fibrinogen and plasma viscosity of the control group were all lower than those of the study group(P<0.05);the levels of CRP,IL-6,and TNF-αin the control group were higher and IL-2 levels in the control group were lower than those in the study group(P<0.05).Conclusion:Western medicine combined with Chinese medicine is more effective in curing damp-heat and stasis-type pelvic inflammatory disease by improving the blood rheological indexes and lowering the level of inflammatory factors.

半夏泻心汤加味联合四联疗法对脾胃湿热型Hp相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响

[目的]探究半夏泻心汤加味联合四联疗法对脾胃湿热型幽门螺杆菌(Hp)相关慢性胃炎患者Hp清除率及胃肠黏膜功能的影响。[方法]收集2020年3月-2022年3月在本院收治的92例脾胃湿热型Hp相关慢性胃炎患者,将患者按照随机法分为对照组45例、研究组47例。对照组患者采用四联疗法予以治疗,而研究组患者则是在对照组的基础上联合半夏泻心汤加味进行治疗,比较两组患者的Hp清除率、胃肠黏膜功能、中医证候积分、胃肠道激素、临床疗效的情况变化。[结果]治疗后两组患者主症、次症积分、丙二醛(MDA)、血管活性肠肽(VIP)表达水平降低,胃泌素-17(GAS-17)、血清胃蛋白酶原I(PGI)、前列腺素E_(2)(PGE_(2))、胃动素、瘦素表达水平升高,且研究组较对照组有所改善(P<0.05)。与对照组比较,研究组的Hp清除率、临床总有效率升高(P<0.05)。研究组的临床总有效率比对照组高(P<0.05)。[结论]半夏泻心汤加味联合四联疗法对治疗脾胃湿热型Hp相关慢性胃炎患者效果显著,可有效减轻患者的中医症状,提升Hp清除率,调节体内的肠道菌群,改善胃肠黏膜功能,值得临床应用。

基于数据挖掘探讨中医治疗脾胃湿热型慢性非萎缩性胃炎的用药规律

目的:探索分析中医药治疗脾胃湿热型慢性非萎缩性胃炎的用药规律。方法:收集中国知网数据库、万方数据库建库至2022年9月1日关于中医药治疗脾胃湿热证慢性非萎缩性胃炎的处方,筛选后导入中医传承计算平台V3.0,对录入处方中药物的使用频次、四气-五味、归经、功效进行分析,采用关联规则、k-means聚类算法进行演算进行分析。结果:共收集91首有效方剂,涉及中药112味。单味药用药频次以黄连最高,半夏次之;药性以寒性、温性为主,平性次之;药味以苦味、辛味最多,辅以甘味;归经中以脾经、胃经为主、肺经次之。功效主要为清热类药、补虚类药、化湿类药、理气类药。常用药物组合频次排前6位的分别为“黄连、半夏”“黄连、陈皮”“半夏、厚朴”“半夏、黄芩”“黄连、黄芩”“半夏、陈皮”;通过k-means聚类得到3对核心药物组合,分别为“黄连、半夏、陈皮、黄芩、厚朴”“厚朴、半夏、黄连、黄芩、甘草”“黄连、半夏、生姜、厚朴、苍术”。结论:中医药治疗脾胃湿热型慢性非萎缩性胃炎以清热燥湿、理气调中为治疗原则,以辛开苦降为重要指导思想,以恢复脾胃气机升降为主要目的,以半夏泻心汤及王氏连朴饮为治疗基础方。此方能通过降低机体炎症水平、抑制胃酸分泌、从而达到促进胃黏膜修复的作用,同时还能改善胃肠道动力,从而减轻患者临床症状,改善预后。

鼻窦排脓饮在脾胃湿热型慢性鼻窦炎行功能性鼻内镜手术患者中的应用效果

目的 探讨鼻窦排脓饮在脾胃湿热型慢性鼻窦炎(CRS)行功能性鼻内镜手术(FESS)患者中的应用效果。方法 选取2020年6月至2022年12月于新余市中医院就诊的CRS患者96例,采用随机数字表法分为两组,各48例。两组均行FESS,对照组采用注射用阿莫西林钠克拉维酸钾联合糠酸莫米松鼻喷剂治疗,观察组加用鼻窦排脓饮治疗,两组均连续治疗4周。对比两组临床疗效、鼻黏膜形态、鼻黏膜纤毛功能、炎症因子水平、中医证候积分及不良反应。结果 观察组临床总有效率较对照组高,治疗后Lund-Kennedy评分、中医证候积分及超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)水平较对照组低,清除速度、清除率较对照组高(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 行FESS的脾胃湿热型CRS患者应用鼻窦排脓饮治疗效果较佳,可促进鼻黏膜形态及功能恢复,减轻炎症反应,促进疾病恢复。

清热除湿汤加减联合IPL治疗轻中度脾胃湿热型玫瑰痤疮疗效研究

目的:探讨清热除湿汤加减联合强脉冲光(Intense pulsed light,IPL)治疗轻中度脾胃湿热型玫瑰痤疮的疗效。方法:选取2018年2月-2021年2月在笔者医院确诊的100例轻中度脾胃湿热型玫瑰痤疮患者,采用简单随机分组将患者分为观察组和对照组,每组50例。对照组采用IPL治疗,观察组采用清热除湿汤加减联合IPL治疗,均持续治疗4个月。评价患者疗效和治疗前后中医证候积分。分别于治疗前后采用玫瑰痤疮医师全球评分(Physician’s global assessment,PGA)对患者玫瑰痤疮情况进行评分;分别于治疗前、治疗后2个月和治疗后4个月,使用皮肤病生活质量指数量表(Dermatology life quality index,DLQI)评估患者生活质量。记录两组治疗期间的不良反应发生情况。结果:观察组治疗有效率为92.00%,明显高于对照组的76.00%,差异有统计学意义(P<0.05);治疗后,观察组中医证候积分明显低于对照组,观察组患者玫瑰痤疮改善程度明显优于对照组,生活质量明显高于对照组,差异均有统计学意义(P<0.05)。观察组患者治疗期间的不良反应发生率为10.00%,与对照组(14.00%)比较差异无统计学意义(P>0.05)。结论:清热除湿汤加减联合IPL治疗轻中度脾胃湿热型玫瑰痤疮可明显提高临床疗效,改善患者生活质量。

健脾和胃汤联合消食膏穴位贴敷治疗脾胃湿热型小儿厌食症的效果及对血清微量元素、食欲调节因子水平的影响

目的 探讨健脾和胃汤联合消食膏穴位贴敷治疗脾胃湿热型小儿厌食症的效果及对血清微量元素、食欲调节因子水平的影响。方法 选择2019年11月至2021年1月收治的200例脾胃湿热型小儿厌食症患儿作为研究对象,根据随机数字表法将其分为对照组与观察组,每组100例。对照组给予基础治疗和双歧杆菌四联活菌片,观察组在对照组基础上加施健脾和胃汤联合消食膏穴位贴敷。比较两组的治疗效果、血清微量元素、食欲调节因子水平及生活质量。结果 观察组的治疗总有效率为97.00%,高于对照组的88.00%,差异具有统计学意义(P<0.05)。治疗1个月后,观察组的铁、锌、硒水平均高于对照组,差异具有统计学意义(P<0.05)。治疗1个月后,观察组的促食欲激素/瘦素、神经肽Y水平均高于对照组,差异具有统计学意义(P<0.05)。治疗1个月后,观察组的健康状况调查表(SF-36)各维度评分均高于对照组,差异具有统计学意义(P<0.05)。结论 健脾和胃汤联合消食膏穴位贴敷治疗脾胃湿热型小儿厌食症的效果满意,可改善血清微量元素和食欲调节因子水平,提升生活质量。

半夏莪术消痞汤治疗脾胃湿热型慢性非萎缩性胃炎临床研究及对胃肠激素水平的影响

目的探讨半夏莪术消痞汤治疗脾胃湿热型慢性非萎缩性胃炎(chronic non-atrophic gastritis,CNAG)的效果及对胃肠激素水平的影响。方法选取2021年1月—2021年7月该院320例脾胃湿热型Hp感染CNAG患者,随机数字表法分为观察组与对照组,每组各160例患者,对照组给予常规西医治疗,观察组在对照组的基础上给予半夏莪术消痞汤,两组均持续治疗14d,比较两组临床疗效、Hp清除率、内镜积分及病理组织学积分、胃肠激素及氧化应激指标水平。结果观察组临床治疗有效率90.00%(144/160)高于对照组81.88%(131/160)(P<0.05);观察组Hp转阴率76.88%(123/160)高于对照组64.38%(103/160)(P<0.05);观察组治疗后内镜检查黏膜红斑、黏膜糜烂、黏膜出血积分以及病理组织学慢性炎症、活动性炎症积分低于对照组(P<0.05);观察组治疗后胃脘疼痛、脘腹痞胀、口黏且苦、泛恶、纳呆、身重困倦、大便黏滞不爽证候积分低于对照组(P<0.05);观察组治疗后血浆胃动素(MOT)、促胃液素(GAS)、胃蛋白酶原Ⅰ(PGⅠ)及PGⅠ/PGⅡ比值水平高于对照组(P<0.05);观察组治疗后丙二醇(MDA)水平低于对照组,超氧化物歧化酶(SOD)水平高于对照组(P<0.05)。结论在常规西医治疗的基础上,联合使用半夏莪术消痞汤治疗CNAG可有效减轻患者临床症状,提高Hp清除率,调节胃肠激素水平,减轻氧化应激。

半夏泻心汤加减治疗脾胃湿热型慢性浅表性胃炎的临床效果观察

目的分析半夏泻心汤加减治疗脾胃湿热型慢性浅表性胃炎的临床效果,旨意为相关人员研究工作提供参考资料。方法选择脾胃湿热型慢性浅表性胃炎196例病患为研究对象。按照治疗法则差异,将患者分为奥美拉唑组(n=98)、中药加减组(n=98)。奥美拉唑组使用奥美拉唑肠溶片治疗;中药加减组使用半夏泻心汤加减治疗,分析结果。结果中药加减组治疗有效率优于奥美拉唑组,两组相比(P<0.05);干预后,中药加减组胃痛、胃胀、胃烧灼、纳差、反酸、嗳气中医症状积分低于奥美拉唑组(P<0.05);干预后中药加减组的SOD值高于奥美拉唑组(P<0.05);中药加减组干预后疾病复发率低于奥美拉唑组,Hp清除率高于奥美拉唑组(P<0.05)。两组病患干预后,未出现不良反应。结论针对脾胃湿热型慢性浅表性胃炎患者来讲,为其使用半夏泻心汤加减治疗疾病能减少疾病复发率、症状积分,增加Hp清除率以及疾病治疗有效率,改善SOD值。建议推广。

黄连温胆汤联合艾司奥美拉唑、阿莫西林二联疗法治疗幽门螺杆菌感染的临床效果

目的观察黄连温胆汤加减联合艾司奥美拉唑、阿莫西林二联疗法治疗脾胃湿热型幽门螺杆菌(HP)感染的临床效果。方法选取2021年1月至2022年6月就诊于上海中医药大学附属光华医院门诊及病房的脾胃湿热型HP感染患者120例,采用随机数表法分为治疗组和对照组,每组各60例,治疗组予黄连温胆汤联合艾司奥美拉唑、阿莫西林二联疗法。对照组予含铋剂的标准四联疗法,两组疗程均为2周,观察两组患者临床疗效、中医证候积分、HP根除情况以及不良反应发生情况。结果治疗前两组中医证候积分比较,差异无统计学意义(P>0.05);治疗后治疗组临床总有效率、HP根除率高于对照组,中医证候积分、不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论黄连温胆汤加减联合艾司奥美拉唑、阿莫西林二联疗法能改善脾胃湿热型HP感染患者临床症状,提高HP根除率,具有较高安全性,值得临床推广。

中西医结合治疗脾胃湿热型慢性胃炎伴Hp感染的疗效分析

目的探讨中西医结合治疗脾胃湿热型慢性胃炎伴Hp感染的疗效分析。方法将2015年2月～2018年2月在我院消化内科治疗的256例脾胃湿热型慢性胃炎伴Hp感染患者根据随机数字表法分为两组,对照组单用西医方法治疗,观察组采用中西医结合治疗,比较两组患者的临床疗效、Hp根除率、症状改善情况、不良反应。结果观察组治疗有效率为96.88%,明显高于对照组的78.91%,差异有统计学意义(P<0.05);观察组Hp根除率为87.50%,明显高于对照组的71.09%,差异有统计学意义(P<0.05);观察组治疗后胃脘灼热、上腹胀痛、恶心呕吐、口苦口臭等中医证候积分明显低于对照组,差异有统计学意义(P<0.05);观察组胸闷、头晕、乏力、腹泻、皮疹等不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论中西医结合治疗脾胃湿热型慢性胃炎伴Hp感染的疗效显著,能提升Hp根除效果,促进症状缓解,且不良反应发生率低,具有积极的临床意义。

清中愈疡汤对脾胃湿热型胃溃疡作用的实验研究

目的:探讨清中愈疡汤对脾胃湿热型胃溃疡的治疗作用,为临床用药提供实验依据。方法:将60只Wistar大鼠随机分为6组,正常对照组、模型对照组、清中愈疡汤高剂量组、清中愈疡汤中剂量组、清中愈疡汤低剂量组、奥美拉唑组,每组10只。正常对照组正常饲养,其余各组均制作为实验性脾胃湿热型胃溃疡大鼠模型。造模成功予以持续治疗30 d后,处死大鼠取其血样和胃黏膜组织。测量计算大鼠溃疡面积及溃疡抑制率;将胃黏膜组织制成病理切片行苏木素伊红(HE)染色,在显微镜下观察各组大鼠胃黏膜组织的病理学变化,并检测大鼠血清中肿瘤坏死因子(TNF-α)、白介素-8(IL-8)、胃动素(MTL)、前列腺素E2(PGE2)等水平,比较干预前后各组相关指标变化情况。通过Western blot法检测大鼠胃黏膜组织中核转录因子κB(NF-κB)通路相关蛋白水平,包括磷酸化核因子κB亚基65(p-NF-κB p65)、磷酸化核因子κB抑制蛋白(p-IκBα)。结果:与正常对照组比较,模型对照组胃黏膜发生明显病理变化,黏膜上皮细胞明显缺损,可见黏膜组织充血及水肿现象,并存在明显炎性细胞浸润。干预后,各组溃疡面积、溃疡抑制率、TNF-α、IL-8、MTL及PGE2水平、NF-κB p65、p-NF-κB p65、IκBα、p-IκBα蛋白表达水平比较,差异均有统计学意义(P<0.05);干预后,与正常对照组比较,模型对照组溃疡面积增加,NF-κB p65、IκBα蛋白表达水平均降低,p-NF-κB p65、p-IκBα蛋白表达水平均升高(P<0.05);干预后,与模型对照组比较,清中愈疡汤高、中、低剂量组及奥美拉唑组溃疡面积均明显减少,TNF-α、IL-8水平均下降,MTL、PGE2水平均升高,(P<0.05);与奥美拉唑组比较,清中愈疡汤高、中剂量组溃疡面积均明显减少,溃疡抑制率均明显增加(P<0.05);与清中愈疡汤低剂量组比较,清中愈疡汤高、中剂量组溃疡面积均明显减少,溃疡抑制率均明显增加(P<0.05)。与清中愈疡汤中剂量组比较,清中愈疡汤高剂量组明显减少,溃疡抑制率明显增加(P<0.05)。与模型对照组比较,清中愈疡汤高、中、低剂量组均出现不同程度的NF-κB p65、IκBα蛋白表达水平升高、p-NF-κB p65下降;清中愈疡汤高剂量组p-IκBα蛋白表达水平低于模型对照组(P<0.05)。结论:清中愈疡汤可通过抑制炎症因子释放以及抑制NF-κB信号通路相关蛋白表达,以减少溃疡面积,并促进胃黏膜内源性物质分泌以及胃活动功能,从而达到对脾胃湿热型胃溃疡的治疗作用,促进溃疡愈合。

清热化湿方辅治慢性糜烂性胃炎脾胃湿热型患者的临床疗效及其对炎性因子的影响

目的：探讨清热化湿方辅治慢性糜烂性胃炎脾胃湿热型患者的临床疗效、安全性、复发率及其对机体炎性因子水平的影响。方法：选取慢性糜烂性胃炎脾胃湿热型126例,随机分为观察组与对照组,每组63例。对照组给予西医常规治疗,观察组在对照组的基础上辅以清热化湿方治疗,两组均治疗4周。评价两组患者治疗前后的炎性因子水平,包括C反应蛋白（CRP）和白细胞介素-6（IL-6）水平,临床疗效以及不良反应,随访6个月观察治疗有效患者的复发情况。结果：治疗前,两组患者的血CRP、IL-6水平比较,差异均无统计学意义（t=0.00-0.97,P〉0.05）。治疗后,两组CRP、IL-6水平均降低（t=3.56-7.31,P〈0.05或P〈0.01）;且观察组CRP、IL-6水平均低于对照组水平（t=3.95、4.20,P〈0.05）。观察组与对照组总有效率分别为90.48%、80.95%（χ2=3.67,P〈0.05）。治疗过程中,观察组与对照组各有1例患者略感轻微恶心,未呕吐;观察组另有1例患者轻微皮肤症状。治疗结束6个月后,随访治疗有效患者,观察组及对照组复发率分别为5.56%、20.00%（χ2=6.77,P〈0.01）。结论：清热化湿方辅治慢性糜烂性胃炎脾胃湿热型患者具有较好的临床疗效,短期治疗后患者的炎症状态得以缓解,临床症状迅速消失或缓解,且具有较高的安全性和较低的复发率,优于单纯西医常规方法。

清化愈疡汤治疗幽门螺杆菌阳性脾胃湿热型消化性溃疡的临床观察

目的评价清化愈疡汤治疗幽门螺杆菌阳性脾胃湿热型消化性溃疡的临床疗效。方法选取2015年6月—2017年7月脾胃病科门诊就诊的幽门螺杆菌阳性的脾胃湿热型消化性溃疡患者80例,采取随机数字表法分为对照组和观察组各40例。对照组患者进行四联抗幽门螺杆菌及质子泵抑制剂抗溃疡治疗。观察组患者在此基础上加服清化愈疡汤。观察2组间内镜下黏膜愈合程度、中医症状积分、幽门螺杆菌根除率的差异。结果观察组内镜下黏膜愈合程度(P <0. 05)、中医症状积分改善情况(P <0. 05)显著优于对照组,幽门螺杆菌根除率(P <0. 05)显著高于对照组。结论清化愈疡汤能促进幽门螺杆菌阳性的脾胃湿热型消化性溃疡患者的胃黏膜修复,促进临床症状缓解,并提高幽门螺杆菌根除率。

半夏泻心汤加减对脾胃湿热型慢性萎缩性胃炎患者免疫功能与炎性因子水平的影响

目的分析半夏泻心汤加减对脾胃湿热型慢性萎缩性胃炎患者临床疗效、免疫功能、血清白细胞介素-2(IL-2)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平的影响。方法选取四川省第二中医医院于2017年6月至2021年2月收治的160例脾胃湿热型慢性萎缩性胃炎患者作为研究对象,采用随机数字表法分为对照组和研究组,各80例。给予对照组患者常规药物治疗(兰索拉唑片、阿莫西林胶囊及克拉霉素胶囊),研究组患者在对照组的基础上使用半夏泻心汤加减辨治,两组患者均连续治疗1个月。比较两组患者临床疗效、主要中医证候积分,CD3^(+)、CD4^(+)、CD8^(+)百分比和CD4^(+)/CD8^(+)比值,以及血清IL-2、IL-6、TNF-α水平。结果治疗后,观察组患者治疗总有效率为93.75%,高于对照组的73.75%;两组患者CD3^(+)、CD4^(+)百分比及CD4^(+)/CD8^(+)比值较治疗前均升高,且研究组高于对照组;两组患者中医证候积分、CD8^(+)百分比、血清IL-2、IL-6、TNF-α水平较治疗前均降低,且研究组低于对照组(均P<0.05)。结论联合应用半夏泻心汤加减治疗能显著提高脾胃湿热型慢性萎缩性胃炎患者的临床疗效与免疫功能,降低机体炎症反应,促进患者临床症状的缓解。

温胆汤加减治疗脾胃湿热型睑板腺功能障碍性干眼症疗效探讨

目的:研究温胆汤加减治疗脾胃湿热型睑板腺功能障碍(MGD)性干眼症的临床疗效。方法:将符合中西医诊断标准的MGD患者62例(124眼)随机分为对照组和治疗组,对照组30例(60眼),治疗组32例(64眼)。对照组应用玻璃酸钠滴眼液点眼,妥布霉素地塞米松眼膏(典必殊眼膏)外涂睑缘,湿热敷,睑板腺按摩;治疗组在对照组基础上给予温胆汤加减治疗(清热化湿、祛瘀散结),并随症加减。观察2组治疗前后睑板腺功能、泪膜破裂时间(BUT)、泪液分泌量(SIt)、角结膜荧光素钠染色(FLS)、中医证候积分变化情况。结果:治疗组总有效率85.94%,高于对照组的71.67%,差异有显著性(P<0.05)。2组睑板腺功能、BUT、SIt、FLS、中医证候积分治疗后均较治疗前改善明显(P<0.05),且治疗组治疗后优于对照组(P<0.05)。结论:应用温胆汤为基础的清热化湿、祛瘀散结法,可有效改善脾胃湿热型MGD的睑板腺功能,延长SIt、BUT,促进角膜上皮恢复,并有效改善患者中医证候。

连朴饮合半夏泻心汤加减治疗慢性浅表性胃炎（脾胃湿热型）的效果

目的 分析连朴饮合半夏泻心汤加减治疗脾胃湿热型慢性浅表性胃炎的临床效果.方法 随机选择2017年1月至2018年6月在我院接受治疗的100例脾胃湿热型慢性浅表性胃炎患者为研究对象,依照治疗方法的不同将患者分为研究组与对照组,各50例.对照组患者给予临床常规西药治疗,研究组患者给予连朴饮合半夏泻心汤加减治疗.比较两组患者的临床治疗效果.结果 治疗后,研究组患者的治疗总有效率为98.0%,高于对照组的74.0%,差异具有统计学意义(P<0.05).治疗后,两组患者的主要中医证候积分均降低,且研究组低于对照组,差异具有统计学意义(P<0.05).治疗后,两组患者充血、水肿、糜烂及出血点发生率均降低,且研究组患者的充血、水肿及出血点发生率均低于对照组(P<0.05).研究组患者的Hp清除率为97.9%,高于对照组的73.0%,复发率为2.1%,低于对照组的18.9%(P<0.05).结论 连朴饮合半夏泻心汤加减治疗脾胃湿热型慢性浅表性胃炎的临床效果确切,能改善症状,有效清除Hp,减少疾病复发,值得临床推广应用.

清热利湿和胃法联合穴位按摩治疗Hp阴性慢性糜烂性胃炎(脾胃湿热型)的临床疗效评价

目的观察清热利湿和胃法联合穴位按摩治疗Hp阴性慢性糜烂性胃炎(脾胃湿热型)的临床疗效。方法将72例中医辨证为脾胃湿热型的慢性糜烂性胃炎患者随机分为对照组和试验组,各36例。2组均口服L-谷氨酰胺呱仑酸钠颗粒,试验组加以清热利湿和胃法(萸芍汤口服)配合穴位按摩治疗,疗程均为28 d。比较2组患者治疗前后中医证候积分、总有效率。结果试验组在改善患者临床症状、总有效率方面明显优于对照组,差异有统计学意义(P<0.05)。结论清热利湿和胃法联合穴位按摩治疗Hp阴性慢性糜烂性胃炎(脾胃湿热型)临床总体疗效较好,促进患者临床症状缓解,预防疾病的反复发作,值得推广应用。